Potential use of methylmethionine sulfonium chloride as a component of combination therapy for peptic ulcer and gastroduodenitis
https://doi.org/10.21518/2079-701X-2018-14-28-32
Abstract
It is known that gastritis, gastroduodenitis and peptic ulcer belong to the group of acid-dependent diseases, which occupy a significant proportion among the digestive system diseases. Despite the use of proton pump inhibitors in therapy, the discovery of an important role of H. pylori infection in the genesis of these diseases and the development of eradication schemes, the urgency of the problem persists due to the development of formidable complications (bleeding, perforation). The modern therapeutic concept of treatment of peptic ulcer (including gastroduodenitis) provides active therapeutic tactics and includes multicomponent drug regimens. Along with proton pump inhibitors, the dietary recommendations, appointment of gastro-cytoprotectors, including ones of natural origin, and the individual approach to the patient in each specific case have not outlived their usefulness. Methylmethionine sulfonium chloride (vitamin U) Gastrarex, which improves the secretory and reparative function of the stomach, may be administered as one of the components of the complex therapy of peptic ulcer and gastroduodenitis.
About the Author
I. G. Pakhomova
Mechnikov North-Western State Medical University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion, 2011, 84: 102-113.
2. Ivashkin VT, Sheptulin AA, Maev IV, et al. Clinical guidelines of the Russian Gastroenterological Association for diagnosis and treatment of peptic ulcer. RJGGT, 2016, 26 (6): 40-54.
3. Gastroenterology: a guide for doctors. Under the editorship of Tkachenko EI. SPb: Publishing House SpetsLit LLC, 2013. 637 p.
4. Uspensky YuP, Suvorov AN, Baryshnikova NV. Helicobacter pylori infection in clinical practice. SPb.: InformMed, 2011. 572 p.
5. Spechler SJ. Peptic ulcer and its complications. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. Philadelphia-London-TorontoMontreal-Sydney-Tokyo, 2002, 1: 747-781.
6. Maev IV, Samsonov AA, Andreev NG, Andreev DN. Important practical results and current trends in the study of diseases of stomach and duodenum. Ros. Journal. Gastroenterol., Hepatol. i Koloproktol., 2012, 4: 17-26.
7. Zimmerman YaS, Mikhaleva EN. Ulcer disease and the immune system. Klin. Med., 2000, 7: 15-21.
8. Салтыков А.Б. Теория функциональных систем и клиническая медицина. Клин. мед., 2008, 1: 4-9. /Saltykov AB. Theory of functional systems and clinical medicine. Klin. Med., 2008, 1: 4-9.
9. Василенко В.Х. Чего мы не знаем о язвенной болезни (пути изучения проблемы). В кн.: Актуальные вопросы гастроэнтерологии. М., 1970. Вып. 1: 3-17. /Vasilenko VKh. What we do not know about peptic ulcer (ways of studying the problem). In the book: Actual questions of gastroenterology. M., 1970. Issue. 1: 3-17.
10. Zimmerman YaS. Peptic ulcer: actual problems of aetiology, pathogenesis, differentiated treatment. In the book: Unsolved and Controversial Problems of Modern Gastroenterology. М.: MEDpress-inform, 2013: 85-107.
11. Yakovenko EP, Ivanov AN, Illarionova YuV, et al. Chronic gastritis: diagnosis and treatment. Pharmateca, 2009, 8: 50-54.
12. Malfertheiner P, Megraud F, O’Morain C, et al. Management of Helicobacter pylori infection – the Maastricht V/ Florence Consensus report. Gut Online First, published on October 5, 2016 as 10.1136/gutjnl-2016-312288.
13. Burget DW, Chiverton KD, Hunt RH. Is there an optimal degree of acid supression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology, 1990, 99: 345-51.
14. Moodlin IM, Sachs G. Acid related diseases. Biology and treatment. D-Konstanz, 1998: 217-41.
15. Ivashkin VT, Maev IV, Lapina TL. The Russian Gastroenterological Association clinical guidelines for diagnosis and treatment of Helicobacter pylori infection in adults. RJGGK, 2018, 28 (1): 55-77.
16. Nishizawa T, Nishizava Y, Yahagi N. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: A systematic review and meta-analysis. J Gastroenterol Hepatol, 2014, 29(Suppl. 4): 20-4.
17. Moskalets OV, Paleev FN, Kotova AA, et al. Pathogenesis of the secondary immune deficiency syndrome and approaches to its treatment. Klin. Med., 2002, 11: 18-23.
18. Nutrition. A guidebook. 5th ed. Edited by Baranovsky AYu. St. Petersburg: Peter, 2017. 1104 p.
19. Nesterova AP, Taits NS. Experience of using Vitamin U in the complex treatment of peptic ulcer. Institute of Nutrition of the Academy of Medical Sciences of the USSR. Vitamin U (S-Methylmethionine) Origin, properties, use. Nauka Publisher, Moscow, 1973: 53-60.
20. Patel AD and Prajapati NK. Review on Bio che mical Importance of Vitamin-U. Journal of Chemical and Pharmaceutical Research, 2012, 4(1): 209-215.
21. http://www.calorizator.ru/vitamin/u.
22. https://foodandhealth.ru/vitaminy/vitamin-u/.
23. Ichikawa T, Ito Y, Saegusa Y, et al. Effects of combination treatment with famotidine and methylmethioninesulfonium chloride on the mucus barrier of rat gastric mucosa. J Gastroenterol Hepatol, 2009, 24(3): 488-492. 23. www.gastrarex.ru.
Review
For citations:
Pakhomova I.G. Potential use of methylmethionine sulfonium chloride as a component of combination therapy for peptic ulcer and gastroduodenitis. Meditsinskiy sovet = Medical Council. 2018;(14):28-32. (In Russ.) https://doi.org/10.21518/2079-701X-2018-14-28-32
Views: 896
Email this article 